Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs

Area of Science:

• Molecular Oncology
• Biomarker Discovery
• Bioinformatics

Background:

• Anticancer target drugs (ATDs) offer improved efficacy and reduced side effects over traditional chemotherapy.
• However, ATD effectiveness is limited in advanced cancers, necessitating personalized treatment strategies.
• Patient response to ATDs varies due to differing molecular targets and intracellular signaling pathways involved in cancer progression.

Purpose of the Study:

• To review the application of molecular pathway activation as a novel biomarker for predicting individual tumor response to ATDs.
• To highlight advancements in gene expression profiling and bioinformatics for quantitative pathway activation analysis.
• To discuss the translation of these findings into clinical oncology for patient-centered cancer therapy adjustments.

Main Methods:

• Utilizing high-throughput gene expression profiling to quantitatively measure pathway activation.
• Employing advanced bioinformatic tools for robust and cost-effective pathway analysis.
• Leveraging machine learning algorithms for the selection of optimal predictive biomarkers.

Main Results:

• Quantitative measurement of pathway activation using gene expression data provides a robust method for biomarker development.
• Bioinformatic tools and machine learning enhance the efficiency and accuracy of identifying predictive biomarkers.
• These advancements facilitate a deeper understanding of individual tumor biology and drug response.

Conclusions:

• Molecular pathway activation represents a new generation of biomarkers for personalized cancer therapy.
• Gene expression profiling combined with bioinformatics and machine learning enables precise prediction of ATD efficacy.
• Translating these molecular insights into clinical practice is crucial for optimizing patient-oriented cancer treatment.